Trial Profile
The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for chronic hepatitis C patients with osteoporosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Eldecalcitol (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Osteoporosis
- Focus Therapeutic Use
- 01 Apr 2015 New trial record